203 related articles for article (PubMed ID: 30590306)
1. Decline in dopamine agonists prescribing and characteristics of drugs prescribed during ambulatory office visits for restless legs syndrome: the National Ambulatory Medical Care Survey 2007-2015.
Kim J; Hartzema AG
Sleep Med; 2019 Feb; 54():238-243. PubMed ID: 30590306
[TBL] [Abstract][Full Text] [Related]
2. Appropriate use of dopamine agonists and levodopa in restless legs syndrome in an ambulatory care setting.
Molokwu OC
Ann Pharmacother; 2008 May; 42(5):627-32. PubMed ID: 18381842
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
[TBL] [Abstract][Full Text] [Related]
4. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists.
Meyers J; Candrilli S; Allen R; Manjunath R; Calloway M
Manag Care; 2012 Oct; 21(10):44-51. PubMed ID: 23156076
[TBL] [Abstract][Full Text] [Related]
5. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
[TBL] [Abstract][Full Text] [Related]
6. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
Littner MR; Kushida C; Anderson WM; Bailey D; Berry RB; Hirshkowitz M; Kapen S; Kramer M; Lee-Chiong T; Li KK; Loube DL; Morgenthaler T; Wise M;
Sleep; 2004 May; 27(3):557-9. PubMed ID: 15164914
[TBL] [Abstract][Full Text] [Related]
7. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
8. Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.
Hankin C; Lee D; Garcia-Borreguero D; Wang Z
J Clin Sleep Med; 2019 Sep; 15(9):1225-1232. PubMed ID: 31538593
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for restless legs syndrome.
Ferini-Strambi L; Marelli S
Expert Opin Pharmacother; 2014 Jun; 15(8):1127-38. PubMed ID: 24745717
[TBL] [Abstract][Full Text] [Related]
10. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.
Winkelman JW
Sleep; 2022 Feb; 45(2):. PubMed ID: 34417810
[TBL] [Abstract][Full Text] [Related]
11. Patterns of treatment for restless legs syndrome in primary care in the United Kingdom.
Martinez C; Finnern HW; Rietbrock S; Eaton S; Chaudhuri KR; Schapira AH
Clin Ther; 2008 Feb; 30(2):405-18. PubMed ID: 18343278
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and therapy of restless legs syndrome in the doctor's office].
Saletu M; Esberger-Chowdhury M; Zeitlhofer J; Deecke L
Wien Klin Wochenschr; 2004 Aug; 116(15-16):552-60. PubMed ID: 15471183
[TBL] [Abstract][Full Text] [Related]
13. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
Geyer J; Bogan R
Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic and Nonpharmacologic Treatment of Restless Legs Syndrome.
Anguelova GV; Vlak MHM; Kurvers AGY; Rijsman RM
Sleep Med Clin; 2018 Jun; 13(2):219-230. PubMed ID: 29759272
[TBL] [Abstract][Full Text] [Related]
15. Role of dopamine receptor agonists in the treatment of restless legs syndrome.
Happe S; Trenkwalder C
CNS Drugs; 2004; 18(1):27-36. PubMed ID: 14731057
[TBL] [Abstract][Full Text] [Related]
16. Restless legs syndrome: pathophysiology and modern management.
Nagandla K; De S
Postgrad Med J; 2013 Jul; 89(1053):402-10. PubMed ID: 23524988
[TBL] [Abstract][Full Text] [Related]
17. Internal medicine: guidance to the diagnosis and management of restless legs syndrome.
Ball E; Caivano CK
South Med J; 2008 Jun; 101(6):631-4. PubMed ID: 18475241
[TBL] [Abstract][Full Text] [Related]
18. Impulse control disorders in Parkinson's disease patients with RLS: a cross sectional-study.
Marques A; Figorilli M; Pereira B; Derost P; Debilly B; Beudin P; Vidal T; Durif F; Fantini ML
Sleep Med; 2018 Aug; 48():148-154. PubMed ID: 29913341
[TBL] [Abstract][Full Text] [Related]
19. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
20. Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome.
Talati R; Phung OJ; Mather J; Coleman CI
Ann Pharmacother; 2009 May; 43(5):813-21. PubMed ID: 19401472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
